Psilocybin molecule:

Image from PubChem

Psilocybin Clinical Trials

The Safety, Feasibility, and Acceptability of Psilocybin Combined With Multidisciplinary Palliative Care in Demoralized Cancer Survivors With Chronic Pain (P-PC)

To see complete record on, please visit this link

Id: NCT05506982

Organisation Name: Emory University

Overal Status: Recruiting

Start Date: November 1, 2022

Last Update: December 7, 2022

Lead Sponsor: Emory University

Brief Summary: This phase I trial evaluates the side effects of psilocybin and how well it works under supportive care conditions in cancer survivors living with demoralization and chronic pain. Cancer patients often experience demoralization, which is characterized by feelings of hopelessness, loss of meaning, and existential distress. Psilocybin psychotherapy, together with multidisciplinary palliative and supportive care, may help treat the anxiety, depression, and chronic pain felt by cancer survivors - defined here as cancer patients from time of diagnosis through the end-of-life.

  • Hematopoietic and Lymphoid Cell Neoplasm
  • Malignant Solid Neoplasm

Total execution time in seconds: 0.19660401344299